Clinical trial · Interventional

MASCT-I Treatment for Advanced Solid Tumor

A Single Arm, Open, Phase I/II Clinical Study of MASCT-I Treatment for Advanced Solid Tumor

NCT02858232CI-TRIAL-00023464unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) is a new immunotherapy that dendritic cells(DC) was induced from autologous peripheral blood. The DC can then be loaded with antigens and re-infused. In vitro, antigen-pulsed DC can stimulate autologous T-cell proliferation and induction of autologous specific cytotoxic T-cells(CTL)，similarly re-infused. The previous research data showed that MASCT had the modest overall response and less adverse effects for Hepatocellular Carcinoma patients. The study is aimed to evaluate the safety of MASCT-1 in patients with advanced solid tumors.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Solid Tumors	Solid Neoplasm	CURATED_BROADER	0.80

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
MASCT-I	Biological	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
solid tumor
description
Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
interventionNames
1. Biological: MASCT-I

Primary outcomes (1)

measure
Incidence of treatment-related adverse events
timeFrame
up to 2 years
description
The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, versio4.0

Secondary outcomes (4)

measure
Objective Response Rate (ORR)
timeFrame
up to 2 years

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

1. Patients with histologically-confirmed, advanced (unresectable) solid tumors（Lung cancer, colon cancer, prostate cancer, soft tissue sarcoma, other rare tumor） who have progressed on standard therapy.
2. With written informed consent signed voluntarily by patients themselves.
3. The time of between Patients enrollment and the end of other anti-tumors therapies≥1 month.
4. ECOG≤2.
5. At least one measurable lesion as defined by RECIST criteria 1.1 for tumors.
6. Life expectancy ≥6 months.
7. With normal cardiopulmonary function.
8. Patients have adequate organ function as defined by the following criteria:

Hemoglobin (HGB) ≥85g/L Absolute neutrophil count (ANC) ≥1.0×10\^9/L White blood cell (WBC) ≥3.0×10\^9/L Platelet count ≥80×10\^9/L Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis Alkaline phosphatase (ALP)≤2.5 UNL Total bilirubin (TBil) of ≤1.5 UNL Blood urea nitrogen (BUN) and Creatinine (Cr) of≤1.5 UNL Albumin (ALB) ≥30g/L

Exclusion Criteria:

1. Pregnant or expecting to pregnant
2. Participated in other clinical trials before screening except of observational study.
3. Refused to provide blood samples.
4. Known allergic history of sodium citrate drugs.
5. Known history of organ transplant, including autologous bone marrow transplantation and peripheral stem cell transplantation.
6. Known active brain metastases
7. The use of immunosuppressive drugs with current or 14 days before enrollment.
8. Active primary immune deficiency.
9. known history of tuberculosis.
10. Active infection, including hepatitis B, hepatitis C virus, or human immunodeficiency virus.
11. Patients with serious infection, hepatopathy, nephropathy, respiratory disease, cardiovascular disease or incontrollable diabetes, etc.
12. Patients have other malignant tumors within 5 years,excluding melanoma and carcinoma in situ of cervix.
13. Clinical signs of heart disease.
14. Treatment with any anti-tumors agent within 28days of first administration of study treatment.
15. The research on the influence of non legal persons, medical or ethical reasons

References

Publications (0)

Data not yet available

No reference posted for this study.